Agressividade terapêutica em fim de vida para doentes oncológicos em Portugal

envie a um amigo share this

Agressividade terapêutica em fim de vida para doentes oncológicos em Portugal

Segunda, 15.02.2021

7 em cada 10 doentes oncológicos que morrem num hospital público em Portugal continental são expostos a cuidados considerados excessivamente agressivos e que podem comprometer a qualidade de vida no seu fim. Os clínicos devem considerar aspetos como o tipo de cancro, estadio de doença, comorbilidades, idade e influência da cultura oncológica do hospital, para ajudar os doentes com cancro a evitarem agressividade terapêutica em fim de vida.


Autores e Afiliações:

Diogo Martins ­Branco1,2, Silvia Lopes3,4, Rita Canario1,5, João Freire2, Madalena Feio6, José Ferraz-Gonçalves7, Gabriela Sousa5, Nuno Lunet8,9, Barbara Gomes1,10

1 Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King’s College London; Bessemer Road, London SE5 9PJ, United Kingdom;

2 Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil; Rua Professor Lima Basto, 1099-023 Lisbon, Portugal;

3 NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa; Avenida Padre Cruz, 1600-560 Lisbon, Portugal;

4 Comprehensive Health Research Centre; Campo Mártires da Pátria 130, 1169-056 Lisbon, Portugal;

5 Medical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil, Av. Bissaya Barreto 98, 3000-075 Coimbra, Portugal;

6 Hospital Palliative Care Support Team, Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Professor Lima Basto, 1099-023 Lisbon, Portugal;

7 Palliative Care Department, Instituto Português de Oncologia do Porto Francisco Gentil, Rua Dr. António Bernardino de Almeida 865, 4200-072 Porto, Portugal;

8 Department of Public Health and Forensic Sciences and Medical Education, University of Porto Medical School, Alameda Prof. Hernâni Monteiro, 4200-319 Porto, Portugal;

9 EPIUnit, Institute of Public Health, University of Porto, Rua das Taipas 135, 4050-600 Porto, Portugal;

10 Faculty of Medicine, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal.



Factors associated with the aggressiveness of care at the end of life for patients with cancer dying in hospital: a nationwide retrospective cohort study in mainland Portugal

Introduction: There is growing concern about the aggressiveness of cancer care at the end of life (ACCEoL), defined as overly aggressive treatments that compromise the quality of life at its end. Recognising the most affected patients is a cornerstone to improve oncology care. Our aim is to identify factors associated with ACCEoL for patients with cancer dying in hospitals.

Methods: All adult patients with cancer who died in public hospitals in mainland Portugal (January 2010 to December 2015), identified from the hospital morbidity database. This database provided individual clinical and demographic data. We obtained hospital and region-level variables from a survey and National Statistics. The primary outcome is a composite ACCEoL measure of 16 indicators. We used multilevel random effects logistic regression modelling (p<0·05).

Results: We included 92 155 patients: median age 73 years; 62% male; 53% with metastatic disease. ACCEoL prevalence was 71% (95% CI 70% to 71%). The most prevalent indicators were >14 days in the hospital (43%, 42–43) and surgery (28%, 28–28) in the last 30 days.

Older age (p<0·001), breast cancer (OR 0·83; 95% CI 0·76 to 0·91), and metastatic disease (0·54; 95% CI 0·50 to 0·58) were negatively associated with ACCEoL. In contrast, higher Deyo-Charlson Comorbidity Index (p<0·001), gastrointestinal and haematological malignancies (p<0·001), and death at cancer centre (1·31; 95% CI 1·01 to 1·72) or hospital with medical oncology department (1·29; 95% CI 1·02 to 1·63) were positively associated with ACCEoL. There was no association between hospital palliative care services at the hospital of death and ACCEoL.

Conclusion: Clinical factors related to a better understanding of disease course are associated with ACCEoL reduction. Patients with more comorbidities and gastrointestinal malignancies might represent groups with complex needs, and haematological patients may be at increased risk because of unpredictable prognosis. Improvement of hospital palliative care services could help reduce ACCEoL, particularly in cancer centres and hospitals with medical oncology department, as those services are usually under-resourced, thus reaching few.


Revista: ESMO Open